"Phase 2 trial with #bavituximab added to #radiation and #temozolomide in newly diagnosed #glioblastoma patients suggests on-target effect: 73% of patients were alive at 12 months. https://t.co/H2mwJHsRR9 @kencchang @BryanDChoi @WTCNeuroscience"